Prostate Cancer Blog for Wives and Partners

The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created — or we feel there is something worth noting — it will be posted here.

Archive of older posts

Help Prostate Cancer Research. Help A Charity, Too.

Liberating Research is looking for men living with prostate cancer (metastatic or recurrent) to help understand their perspective on diagnosis and treatment. There are two ways to participate if you live in New York, Los Angeles, or San Francisco: via telephone or in a face-to-face interview. Your opinions will help improve future educational materials for healthcare practitioners. If eligible, you will be paid for your participation (10% goes to a charity). Time is limited. Make your voice known! May 19, 2017.

Prostate Cancer Cured in Mice

Researchers have been able to cure invasive prostate cancer in mice using an existing anticancer drug (cabozantinib). The drug worked by encouraging prostate cancer tumor cells to secrete substances that attracted neutrophils—which are produced in the bone marrow—to enter the tumor and created an immune response that led to an almost complete clearance of tumors, according to a ScienceDaily report. Let’s hope that the drug works just as well in humans some day. Clinical trials are planned to assess using cabozantinib in combination with T-cell immunotherapy for prostate cancer. May 9, 2017.

Can Metastatic Prostate Cancer Be Cured?

Researchers (Matthew et al) are hopeful that a triple combination of hormone therapy, surgery, and radiation may be able to eliminate detectable disease in some men with metastatic prostate cancer. In a very small pilot study, 20 men were treated with androgen deprivation therapy, radical prostatectomy, and radiation treatment. Of that number, 14 men who had prostate cancer metastases to the bone had undetectable PSA for up to 46 months following all 3 treatments. While this is optimistic news for men with metastatic prostate cancer, a larger clinical trial is needed to confirm the findings. April 25, 2017.

Biopsy Alternative On the Horizon?

Researchers at Washington State University are exploring a noninvasive device that analyzes blood and urine to help diagnose prostate cancer and assess extent of disease progression. The device is like a filter that isolates markers of prostate cancer from blood and urine. It uses a mat of tiny glass springs that contain biomarkers that attract exosomes; fatty droplets of proteins and RNA that prostate cancer tumors release into body fluids (like blood and urine) and contain useful genetic information. It is still in the early research phase, but it would be a welcome alternative to biopsy, which can be a very uncomfortable procedure for men. March 28, 2017.

Antidepressants to Prevent Spread of Prostate Cancer?

An antidepressant called clorgyline may block an enzyme called MAOA that helps prostate cancer cells spread to the bone, according to a new animal (mouse) study (Wu et al) that was published in Cancer Cell. While clorgyline is no longer used by doctors, researchers will begin studying other antidepressants that have a similar mechanism of action. March 20, 2017.

More Reasons to Eat Your Broccoli

The green veggie may be good for preventing prostate cancer, according to findings from researchers from Oregon State University, which were published in the Journal of Nutritional Biochemistry. Specifically the compound sulforaphane from broccoli may provide insights on how prostate cancer develops and progresses. The compound appears to affect long, non-coding ribonucleic acids (RNAs), which possibly help “trigger” malignant prostate cancer cells. This may signal the start of more researchers exploring dietary avenues to help prevent or treat the disease. March 17, 2017.

Good News: Metastatic Prostate Cancer Deaths Declining

Fewer men are dying from metastatic prostate cancer, according to a poster that was presented at the 2017 Genitourinary Cancers Symposium held in Orlando, Florida. Researchers looked at data from 6,874 men with prostate cancer from the Danish Prostate Cancer Registry, which were divided into 3 groups based on the year they were diagnosed (1995-2000, 2001-2005, and 2006-2011). Mortality related to prostate cancer decreased by about 10% between the 1995-2000 and 2001-2005 groups. New and advanced treatment options may be the reason. February 21, 2017.

Study: Survival Benefit of Hormone Therapy Plus Radiation

Men with recurrent prostate cancer following surgery should combine hormone therapy with radiation treatment, according to results of a new Cedars-Sinai study published in the New England Journal of Medicine that followed 761 men with prostate cancer over a period of 12 years. The group of men who only had radiation therapy had a 13.4% incidence of death while the incidence of death was 5.4% for men who had combined radiation and hormone therapy. Combined therapy may also help lower the chance of cancer spreading (23% incidence of metastasis for radiation alone vs 14.5% for radiation and hormone treatment). This study confirms other studies that have shown that combination therapy is more effective than radiation alone for recurrent prostate cancer. February 7, 2017.

It's Movember!

Men everywhere are invited to grow their mo (mustache or moustache outside the US) to save a bro. The charity raises funds to support men's health and to stop men from dying too young. Simply grow and groom your mustache. Mo Sistas can also support the Mo and their men. Visit the charity website to learn more.

Continue reading "It's Movember!"

Study: Hormone Treatment And Risk of Dementia

Men who undergo androgen depravation therapy (ADT) may be at increased risk for dementia, according to a new retrospective study (Nead et al) published online in JAMA Oncology. Researchers look at the records of 9,272 men with prostate cancer. They found that after 5 years, 7.9% of men who received ADT had an increased risk of developing dementia vs 3.5% in men who did not have ADT. While some media outlets portray these results as definitive, we would feel more comfortable if similar results were confirmed in more robust randomized clinical trials. But these results are definitely something to discuss with your healthcare provider prior to starting ADT treatment. October 18, 2016.

Stop Giving Men the Finger?

Authors of a study (Ciu et al) published in Current Medical Research and Opinion suggest that digital rectal exam (DRE) screening may add little benefit. Researchers found that only an additional 2% of men who had normal PSA levels had abnormal DREs when analyzing data from 5,064 men from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial. Only 99 of those men who had normal PSA levels were diagnosed with clinically significant prostate cancer (CSPC). When looking at men who had both abnormal PSA and DRE, 20% were diagnosed with CSPC. It should be noted that the PLCO has been criticized for several factors, including low numbers of African-American men and lack of (or inconsistent) biopsies. September 30, 2016.

Early Diagnosis of Prostate Cancer Continues to Fall

In 2012, the U.S. Preventive Services Task Force issued a final guideline recommending that men should not be routinely screened for prostate cancer. As a result, the number of men who are being diagnosed in the US with early prostate cancer declined by 19% in 2012 and fell another 6% in 2013, according to a HealthDay News report. We predict that this trend will continue until our government comes to its senses and the pendulum swings back again. September 27, 2016.

Study: Similar Survival Rates At 10 Years With or Without Treatment

Men with localized prostate cancer may be just as likely to survive without treatment after 10 years as men who opt for surgery or radiation, according to a new UK study published in the New England Journal of Medicine (Hamdy et al). The study followed 545 men with prostate cancer who had active monitoring, 533 men who had radical prostatectomy, and 545 who had radiation (median age was 62 years). The majority of men (77%) had a Gleason sore of 6. Researchers found that death due to prostate cancer at 10 years was low (about 1%) regardless of the type of treatment. September 23, 2016.

Study: Hormone Therapy May Not Be As Effective for African American Men

African American (AA) men with prostate cancer had an increased likelihood of dying after receiving androgen deprivation therapy (ADT) for an average of 4 months than non-AA men, according to a new study (Konstantin et al), as reported by Brigham and Women’s Hospital that was published in the August 4 issue of Cancer. First, this was a retrospective study that analyzed the medical records of 7,252 men with low or favorable-intermediate risk of prostate cancer (20% of those men had ADT prior to brachytherapy). A lot of factors can come into play in a retrospective study. But it is noteworthy to report that the AA men had a 77% higher risk of death. Randomized clinical trials are needed to confirm these results. August 9, 2016.

Continue reading "Study: Hormone Therapy May Not Be As Effective for African American Men"

Study: Men With Metastatic Prostate Cancer Might Consider Genetic Testing

Researchers have linked inherited mutations in DNA-repair genes (such as BRCA2) with a greater risk of lethal prostate cancer. But men with localized prostate cancer (cancer that is confined to the prostate gland) usually do not undergo routine genetic testing because the incidence of having DNA-repair gene mutations is low (1.2% to 1.8% for BRCA2 alone). In a recent study (Pritchard et al), however, researchers found that these DNA-repair gene mutations were present in 12% of 82 men with metastatic cancer, prompting the suggestion that “it may be of interest” to routinely examine all men with metastatic prostate cancer for genetic testing. But the researchers admit there were multiple limitations with this study, which appeared online first last week in the New England Journal of Medicine. July 12, 2016.

Continue reading "Study: Men With Metastatic Prostate Cancer Might Consider Genetic Testing"

Always consult a medical professional.

Page copy protected against web site content infringement by Copyscape
Search site
Search site